244 related articles for article (PubMed ID: 25958319)
21. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA; Grisham RN; O'Cearbhaill RE; Boucicaut NN; Henson M; Iasonos A; Zhou Q; Sarasohn DM; Gallagher J; Kravetz S; Zamarin D; Makker V; Sabbatini PJ; Tew WP; Aghajanian C; Konner JA
Gynecol Oncol; 2020 Apr; 157(1):214-221. PubMed ID: 31959492
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
Miller DS; Filiaci VL; Mannel RS; Cohn DE; Matsumoto T; Tewari KS; DiSilvestro P; Pearl ML; Argenta PA; Powell MA; Zweizig SL; Warshal DP; Hanjani P; Carney ME; Huang H; Cella D; Zaino R; Fleming GF
J Clin Oncol; 2020 Nov; 38(33):3841-3850. PubMed ID: 33078978
[TBL] [Abstract][Full Text] [Related]
23. Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation.
Fowler JM; Brady WE; Grigsby PW; Cohn DE; Mannel RS; Rader JS
Gynecol Oncol; 2009 Mar; 112(3):553-7. PubMed ID: 19135232
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
25. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC
Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720
[TBL] [Abstract][Full Text] [Related]
27. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
[TBL] [Abstract][Full Text] [Related]
29. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
30. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
[TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
Taylor SE; Li R; Petschauer JS; Donovan H; O'Neal S; Keeler AW; Zamboni WC; Edwards RP; Zorn KK
Gynecol Oncol; 2015 Sep; 138(3):548-53. PubMed ID: 26111788
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.
Homesley HD; Filiaci V; Gibbons SK; Long HJ; Cella D; Spirtos NM; Morris RT; DeGeest K; Lee R; Montag A
Gynecol Oncol; 2009 Mar; 112(3):543-52. PubMed ID: 19108877
[TBL] [Abstract][Full Text] [Related]
35. [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
Honma H; Sagae S; Terasawa K; Tanaka R; Chida M; Mizumoto H; Ishioka S; Saito T; Kudo R
Gan To Kagaku Ryoho; 2004 Apr; 31(4):549-53. PubMed ID: 15114698
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
Konner JA; Grabon DM; Gerst SR; Iasonos A; Thaler H; Pezzulli SD; Sabbatini PJ; Bell-McGuinn KM; Tew WP; Hensley ML; Spriggs DR; Aghajanian CA
J Clin Oncol; 2011 Dec; 29(35):4662-8. PubMed ID: 22067389
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial.
Onda T; Katsumata N; Tsunematsu R; Yasugi T; Mushika M; Yamamoto K; Fujii T; Hirakawa T; Kamura T; Saito T; Yoshikawa H
Jpn J Clin Oncol; 2004 Sep; 34(9):540-6. PubMed ID: 15466828
[TBL] [Abstract][Full Text] [Related]
40. Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
Smith HO; Moon J; Wilczynski SP; Tiersten AD; Hannigan EV; Robinson WR; Rivkin SE; Anderson GL; Liu PY; Markman M
Gynecol Oncol; 2009 Aug; 114(2):206-9. PubMed ID: 19464730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
